New research suggests that people who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional lifestyle regimens.
Findings released in a leading medical journal points out that while obese individuals often shed a large proportion of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these medications must be aware of the risk of fast rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of regain means a return to pre-treatment weight in about one and a half years.
Weighing Approaches
The research, which examined dozens of studies involving over 9,000 of participants, compared the results of these new drugs with older methods.
Scientists point out that individuals who shed pounds through dieting usually experience a less rapid weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Doctors believe the mode of action of the drugs explains the amplified regain.
These medications imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making overeating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals say that, considering the significant potential of weight regain, the therapy is often long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "underscore the chronic nature of obesity," similar to managing conditions like diabetes.
Patient Accounts
People who have stopped the medication explain a sudden return of hunger.
"It felt as if a switch activating and you become ravenous," described one woman.
This challenge is exacerbated if users have not adopted sustainable dietary or behavioural changes during therapy.
Significant Adoption
Figures suggest that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is more common among women than males.
- The 40s and 50s age group shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone fix and lasting health benefits relies on ongoing behavioural support.
